Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM41GRA)

• Drug Name: Ceftazidime Drug Info
• Synonyms: Ceftazidima; Ceftazidimum; Ceptaz; Fortaz; Ceftazidime Sodium In Plastic Container; Ceftazidime anhydrous; Ceftazidime pentahydrate; Fortaz In Plastic Container; SN 401; CEFTAZIDIME (ARGININE FORMULATION); Ceftazidima [INN-Spanish]; Ceftazidime (INN); Ceftazidime (TN); Ceftazidimum [INN-Latin]; Cefzim (TN); Ceptaz (TN); Fortaz (TN); Fortum (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
• Therapeutic Class: Antibiotics
• Cross-matching ID:
  PubChem CID: 5481173
  ChEBI ID: CHEMBL44354
  CAS Number: CAS 72558-82-8
  TTD Drug ID: D0PH5Z
  VARIDT Drug ID: DR00659

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Mismatch repair	1.93	5.47e-3	22/23 (95.65%)	PCNA;MSH2;MSH6;...
PPAR signaling pathway	-1.71	3.31e-2	66/74 (89.19%)	APOA2;RXRA;PLTP;...
Regulation of actin cytoskeleton	-1.72	3.42e-2	185/218 (84.86%)	FGF22;ITGA10;ARPC1B;...
ErbB signaling pathway	-1.72	3.62e-2	79/85 (92.94%)	CAMK2A;RPS6KB2;BRAF;...
Regulation of lipolysis in adipocytes	-1.72	3.84e-2	52/55 (94.55%)	AKT2;PNPLA2;AQP7;...
Nitrogen metabolism	-1.72	4.10e-2	16/17 (94.12%)	CA7;CA14;CA6;...
Complement and coagulation cascades	-1.73	3.97e-2	76/85 (89.41%)	A2M;C6;SERPIND1;...
Proteoglycans in cancer	-1.73	4.05e-2	172/205 (83.9%)	FZD9;ROCK2;WNT7A;...
Biosynthesis of unsaturated fatty acids	-1.75	3.66e-2	21/27 (77.78%)	ACOT7;FADS2;ELOVL4;...
Protein digestion and absorption	-1.80	2.26e-2	78/103 (75.73%)	COL18A1;SLC7A8;SLC1A5;...
NF-kappa B signaling pathway	-1.81	2.20e-2	90/104 (86.54%)	DDX58;TRAF3;NFKB2;...
Malaria	-1.83	1.95e-2	44/50 (88%)	SELP;GYPB;TGFB1;...
TNF signaling pathway	-1.83	2.20e-2	103/112 (91.96%)	MAPK8;CEBPB;BIRC2;...
Legionellosis	-1.86	1.05e-2	51/57 (89.47%)	CLK4;NFKB2;RAB1B;...
Arginine biosynthesis	-1.86	1.22e-2	17/22 (77.27%)	GLS;GPT;NOS2;...
Amoebiasis	-1.88	1.17e-2	99/102 (97.06%)	GNA15;COL3A1;CSF2;...
Rheumatoid arthritis	-1.90	1.46e-2	78/93 (83.87%)	ATP6V1C1;CXCL6;CSF2;...
Terpenoid backbone biosynthesis	-1.91	1.46e-2	18/22 (81.82%)	IDI1;MVD;ACAT1;...
IL-17 signaling pathway	-2.24	0.00e+0	84/94 (89.36%)	S100A8;MUC5B;JUND;...
Steroid biosynthesis	-2.25	0.00e+0	19/20 (95%)	CYP51A1;MSMO1;SQLE;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Hide ▲